Company Overview and News
2018-10-05 seekingalpha - 1
This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to take profit and to diversify. In recent weeks, I've written articles about the 19 new positions, so this review will be a brief summary.
TXN CNUTF XOM RDSB ENB OPRF RDSA FTS WMT BCE CSCO ABBV DUKH BAMGF SO UPS MAIN TYT KMB CMI ENB MFC RY 0945 BNS JNJ ITW RYDBF 7203 WPC SPG ABBV MSFT QCOM PFE CLX CDUAF BAMKF NNN SOJA TM ADP SKT EPD TD ETN BNS MSCA AAPL BIP RYDAF TD CSCOI BAM BEP CU VTR IBM RDS.B RY RDS.A TNTTF APLE O DUK FDX TOYOF MSCA.CL BLK HP PEP ADPVV FTS PPL MFC
Merrill Lynch estimates the typical retired couple needs $738,400 to be financially secure over a 30-year retirement.
August marks the 10th month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $1,665.95.
SOJA GIS XOM IDCC SKT LTC ENB OPRF BPL SEP COP MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI WLKP ENB ETP HP ORI SPG WPC ADM
July marks the ninth month I have officially tracked the taxable account's dividend income. The total amount of dividend income received was $640.87.
SOJA GIS XOM SKT LTC OPRF SEP BPL MIC CINF AAPL CAH EMR SO TLP WLK O MSB CMI ETP ORI WPC SPG ADM
Tanger Factory Outlet Centers (NYSE:SKT) has become a battleground stock. Some 27% of Tanger stock is sold short at the moment. And of late, the shorts have taken a bit of beating. Heading into its most recent earnings report, Tanger stock had bounced 20% from May lows. And a 2.1% gain in after-hours trading after an earnings beat could add to the pain from the short side.
SKT SPG GGP MAC WPG CBL
Document United States
Document United States
The following slide deck was published by Tanger Factory Outlet Centers, Inc. in conjunction with their 2018 Q2 earnings call.
Document UNITED STATES
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to SKT / Tanger Factory Outlet Centers, Inc. on message board site Silicon Investor.
as of ET